This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Università Degli Studi Dell'aquila. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Innovations in RNA Therapeutics by Mattia Capulli
Introduction
Mattia Capulli is an innovative inventor based in L'Aquila, Italy. He has made significant contributions to the field of molecular biology, particularly in the development of small interfering RNA (siRNA) for therapeutic applications. His work focuses on addressing genetic disorders, showcasing the potential of RNA-based therapies.
Latest Patents
Mattia Capulli holds a patent for a groundbreaking invention titled "Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation." This invention lies in the field of molecules known as small interfering RNA, which have the ability to reduce gene expression in a highly specific manner. siRNAs are small sequences of double-strand RNA that have revolutionized cell biology by enabling previously unattainable molecular manipulations.
Career Highlights
Mattia Capulli is affiliated with the Università degli Studi dell'Aquila, where he conducts research and develops innovative solutions in the field of molecular therapeutics. His work has garnered attention for its potential to transform treatment options for genetic disorders.
Collaborations
Mattia collaborates with esteemed colleagues, including Anna Maria Teti and Nadia Rucci, who contribute to his research endeavors and enhance the impact of his work in the scientific community.
Conclusion
Mattia Capulli's contributions to the field of RNA therapeutics exemplify the innovative spirit of modern science. His patent on siRNA for genetic therapy highlights the potential for targeted treatments in addressing complex genetic disorders.